logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12441689 B1

PDFFull Text
Date of Patent:
Oct. 14, 2025

Filed:

May. 14, 2020

Acss2 inhibitors and methods of use thereof

Applicant:

Epivario, Inc., Philadelphia, PA (US);

Inventors:

Philippe Nakache, Ness Ziona, IL;

Omri Erez, Rehovot, IL;

Simone Botti, Rehovot, IL;

Andreas Goutopoulos, Boston, MA (US);

Harry Finch, Bedfordshire, GB;

Assignee:

EpiVario, Inc., Philadelphia, PA (US);

Attorney:

Meunier Carlin & Curfman LLC

Primary Examiner:

Erich A Leeser

Int. Cl.
CPC ...
C07D 231/22 (2006.01); A61K 31/4152 (2006.01); A61K 31/4155 (2006.01); A61K 31/4184 (2006.01); A61K 31/422 (2006.01); A61K 31/427 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); A61P 3/00 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); C07D 231/20 (2006.01); C07D 231/26 (2006.01); C07D 233/70 (2006.01); C07D 401/04 (2006.01); C07D 401/10 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/10 (2006.01); C07D 403/12 (2006.01); C07D 405/04 (2006.01); C07D 405/10 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/04 (2006.01); C07D 409/12 (2006.01); C07D 413/10 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07F 5/02 (2006.01);
U.S. Cl.
CPC ...
C07D 231/22 (2013.01); A61K 31/4152 (2013.01); A61K 31/4155 (2013.01); A61K 31/4184 (2013.01); A61K 31/422 (2013.01); A61K 31/427 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); A61P 3/00 (2018.01); A61P 25/00 (2018.01); A61P 29/00 (2018.01); A61P 31/12 (2018.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); C07D 231/20 (2013.01); C07D 231/26 (2013.01); C07D 233/70 (2013.01); C07D 401/04 (2013.01); C07D 401/10 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/10 (2013.01); C07D 403/12 (2013.01); C07D 405/04 (2013.01); C07D 405/10 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/04 (2013.01); C07D 409/12 (2013.01); C07D 413/10 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07F 5/025 (2013.01);
Abstract

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

Find Patent Forward Citations

Loading…